Published in Medical Letter on the CDC and FDA, November 18th, 2001
The supplemental new drug application (sNDA) for Diovan for heart failure was filed with the FDA on April 27, 2001, by Novartis Pharmaceuticals Corp., and was granted priority review status. The Diovan filing is based on the positive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.